| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9601420 | Clinical Oncology | 2005 | 6 Pages |
Abstract
Combination chemotherapy with gemcitabine and cisplatin plus trastuzumab is well tolerated and active in patients with HER2 overexpressing MBC, even after prior exposure to anthracyclines and taxanes.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
H.J. Stemmler, S. Kahlert, O. Brudler, M. Beha, S. Müller, B. Stauch, V. Heinemann,